A Comprehensive Approach to Preventing Virological Failure ... Comprehensive Approach to...
Transcript of A Comprehensive Approach to Preventing Virological Failure ... Comprehensive Approach to...
Vincent Marconi, MDProfessor of Medicine and Global Health
Emory University School of Medicine
Rollins School of Public Health
Emory Vaccine Center
A Comprehensive Approach to Preventing VirologicalFailure in South Africa
1
At the time this presentation was given, I had no real or perceived vested interests that related to this presentation, nor did I have any
relationships with pharmaceutical companies, biomedical device manufacturers, and/or other corporations whose products or services are related to pertinent therapeutic areas. However, I have consulted
for or received research funding from Lilly, ViiV, Gilead and Bayer.
Vincent Marconi
Disclosure
36.9 million people living with HIV
25.7 M (70%) in SSA
7.2 M (20%) in SA
21.7 million people receiving ART
15.4 M (60%) in SSA
4.4 M (61%) in SA
UNAIDS 2018 3
ART Need and Coverage
SOUTH AFRICAN HIV AND TB INVESTMENT CASE, SANAC AND NATIONAL DEPARTMENT OF HEALTHTanser Science 2013
Increased ART Coverage =
Decreased Infections
Increasing number of HIV+
individuals requiring ARTOngoing HIV transmission
Universal Test and Treat (UTT)
Expanding ART coverage (>50%)
Decreasing mortality among treated
Public Health Dilemma
UNAIDS 2018
Limited capacity and resources to
manage existing patients on ART
GAP = 26%
Goal: Increase Virological Suppression
Describe prevalence of
VF and HIVDR
Identify risk factors for VF
Design strategies to mitigate VF
Goal: Increase Virological Suppression
Describe prevalence of
VF and HIVDR
Identify risk factors for VF
Design strategies to mitigate VF
Question 1: How High is Pretreatment Drug Resistance in KwaZulu-Natal?
Please make your selection...A. 0-4%
B. 5-9%
C. 10-14%
D. >14%
E. I do not know what pretreatment drug resistance is
• A detectable HIV viral load on ART usually represents ongoing viral replication
• Ongoing viral replication has the following consequences– CD4 decline
– Clinical events (OI’s, cancer, neurocognitive decline, end-organ disease)
– Drug resistance mutations (compromising ART)
– HIV transmission
Transmitted DR Prevalent DR
1 year
5 years
10 years
Transmitted HIV Drug Resistance
Blower AIDS 2005
0
10
20
30
40
50
60
70
80
90
≥ 1 signif mutation
DualClass
TripleClass
NRTI NNRTI PI
Pe
rce
nta
ge
of
Su
bje
cts
Marconi CID 2008
Murphy AIDS 2010SARCS Average rate of VF at 12 mos: 4-8%
Second-line LPV/r 65-78% suppression*d4T+3TC+NNRTI
Initial Description of VF/HIVDR after First-Line ART* in South Africa
AIDS 2012
70% of patients failing TDF had K65R
Sanger sequencing missed 30% (Casadella AIDS 2016)
First description of K65R after TDF use in Southern Africa
Lancet ID 2016
Lancet ID 2016
Brenner AIDS 2006
High rate of HIVDR (3TC/FTC and NNRTI)Concern for K65RTAM transmissionLow VF rate
Summary
Francois Venter
Rural KZN 12-40% (Mutevedzi Bull WHO 2010)
SA NHLS with 30% overall VL >400
Validate VF rate, HIVDR prevalence, risk factors in peri-urban and rural settings (FDC)Determine role of minority resistanceIdentify impact of drug concentrationsCreate a risk calculatorHost genetics
KZN HIV Drug Resistance Surveillance Study(DReSS)
R01 AI098558
McCord
HospitalRK Khan
Hospital
Bethesda Hospital
Mkuze
Bethesda CDC
Jozini
Bethesda Hospital and Clinics
Selvan Pillay
Alex Edwards MPH
92%/85%
K65R=22-26%
Gupta Lancet HIV 2017
Adults > 10%
Uganda, Namibia, South Africa,
Zimbabwe, Nicaragua,
Guatemala, Argentina
Infants <18 months 50-55%
Mozambique, Swaziland,
Uganda, Zimbabwe, South
Africa
Pre-Treatment Drug Resistance (PDR) is increasing
worldwide especially in eastern and southern Africa
Now South
Africa
>14%!
Chimukangara Eclin Med 2019
Over the next 15 years in sub-Saharan Africa alone if current first-line ART remains unchanged and PDR >10%, then there will be an additional*
890,000 deaths
450,000 new infections
ART program cost of $6.5 billion
Recommend for these countriesPretreatment HIVDR testing for all or high risk patients
Dolutegravir as first-line
*Phillips JID 2017
WHO Recommendations
Goal: Increase Virological Suppression
Describe prevalence of
VF and HIVDR
Identify risk factors for VF
Design strategies to mitigate VF
Question 2: Do you see your primary provider at least twice annually?
Please make your selection...
A. Yes
B. No
Question 3: If not, why?
Please make your selection...
A. Too busy/takes too long
B. Did not feel sick
C. More important things to do
D. I forgot
E. Visit costs too much
F. Do not like my provider
G. Other
“One Size Fits All”“Tailored Therapy”
Targeted Approach
What is the most effective healthcare delivery model for HIV?
Assess factors at individual clinics which are known to create situations favourable to the emergence of HIVDR
Provide an alert to clinic and ART programs --opportunity for corrective action
Indicators exist for adults and children
Bennett DE et al., Antivir Ther 2008
HIVDR Early Warning Indicators (EWI)High-
priority element
Site
EWI 1: On-time
Pill Pick-up
EWI 2: Retention
in Care
EWI 3: Pharmacy
Stock-outs
EWI 4: Dispensing
Practices
EWI 5: Virological
Suppression
1 95% 75% 100% 70% -
2 70% 50% 100% 15% -
3 100% 75% 75% 0% 95%
4 85% - 100% 0% 78%
5 98% 95% 0% 50%
… … … … … …
100 100% 100% 100% 0% 100%
National Level Reporting
Collated results provide a national levelAt-a-glance assessment of site performance
Biopsychosocial Model
Adapted from Munoz 1996
Patient
Social Ecological Model
Bronfenbrenner 1979
Socioeconomic, Cultural and Psychological Determinants of Health
Toxicity, AdverseEffects, TolerabilityTreatment Fatigue
Access to Potent cART(Properly prescribed
Combinations)
AcceptanceAdherenceand Uptake
BehavioralSocioeconomic and
Cultural Factors
PharmacokineticsAbsorptionMetabolismDrug Interactions
Systemic and Intracellular
Concentration
Increased Immune ActivationImmunologic DeclineDisease ProgressionIncreased TransmissionPoor QOL and High Mortality
Ongoing Viral Replication
Viral ReplicationCapacity, Virulence
and Resistance
Host Immune andIntrinsic Factors
Inhibition of Viral Replication
Decreased Immune ActivationImmune ReconstitutionArrested Disease ProgressionDecreased TransmissionImproved QOL and Survival
Nachega/Marconi IDDT 2011
Determinants of ART Response
Symptoms/QoL
Psychosocial
Barriers to Care
Peltzer BMC Public Health 2010
Bhat Euro J Clin Microb ID 2010
Maqutu AIDS Beh 2010
Sarna Pub Health Rep 2010
Coetzee AIDS Beh 2013
Tired of taking ARVs
Fear of taking ARVs in front of others
Difficulty swallowing
Remembering to take pills
Side effects
Cost of meds
Barriers to Adherence
Economic
Transportation
Food Insecurity
Disability Grants
Poor social support
Institutional
Long wait times
Negative staff experiences
Poor health literacy
Limited substance abuse treatment and mental health facilities
Sociocultural
Perceived stigmatization
Influence of charismatic churches
Traditional healers
Gender Inequalities
Political
Migration
Controversy over provision of HIV Tx
Unfavorable policies
Kagee J Health Pscyhol, Global
Public Health 2010
Western Cape
Barriers to Clinical Care
Probability of Virologic Failure
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
PCAR and MPR
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
group MPR PCAR
Pro
bab
ility
of
VF
Probability of Virologic Failure
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
PCAR and MPR
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
group MPR PCAR
Pill Count Adherence (PCAR) or Medication Possession Ratio (MPR)
Wu CHIVR 2014
Peng Wu, MPH
Brent Johnson, PhD
Created a new adherence metric = PCAR
Probability of VF by Access or Adherence
Vella JAIDS 2010
New patients per year
Staff training and time commitment
Patient:staff ratio
Secure area
Confidentiality
Poor treatment
30
Institutional
Automobile ownership
Financial insecurity:Unemployment
Non-spouse family paying for care
Staying with family other than spouse
Hare AIDS Beh 2014
Anna Hare, MD
Claudia Ordonez, MA
MSF
Colors
31
Economic: Men with Cars vs. Dependent Women
~80% Africans use TAM (WHO 2008)
84% use > 1x for HIV; 32% concurrent1
Adherence barrier, under-reporting2
Sutherlandia, St. John’s Wort, garlic, and American ginseng CYP 450 DDI3
Potential toxicities4
SARCS and RFVF Study5
50-80% prior to ART
5-20% after ART initiation
No relationship to drug resistance, virologic failure or clinical events
Patients report stronger relationships and feel their psychosocial and symptom needs were addressed
1 Babb 20072 Dahab & Reid 2008 3 Hsiao 20034 Mills 2005, Lee 2006, Izzo 20095 Marconi CID 2008, Murphy AIDS 2010, Sunpath
AIDS 2012, Marconi AIDS Pt Care STDs 2013, Appelbaum GPH 2014
32
Sociocultural: Traditional African Medicine
Neighborhood SES effect independent of individual SES
Implies contextual (not only compositional) effects such as geography/transportation and culture
Daniella Coker, MPH
Enoch Chen, MPH
Chen AIDS Beh 2019
Political: Neighborhood Impact
• >1 HIV+ partner/family member
• >1 family member die of HIV
• Disclosing HIV status to friends
• Not actively practicing their faith
• Depression
Rachel Kearns, MPH
Sally John, PhD
John NV Psych 2017
MSF
Colors
34
Psychosocial: Stigma, Faith and Depression
Marconi AIDS Pt Care STDs 2014
Institutional, Community and Societal Factors
Access
VL
Adherence
“The lines are too long”
“I forget to take my pills”
“I miss appointments because the clinic is too
far to travel”
“I miss appointments because the clinic is
crowded”
“I do not take my pills if I have to take it in front of
others”
“I do not like to take my pills as they make me feel
sick”
“My pastor says I should not take
ARVs”
“I feel too tired to go to the clinic”
Baseline (While Initiating
or Suppressed on ART)
On ART Without
Access/Adherence
Measures*
On ART With
Access/Adherence
Measures*
Age
Gender
Faith
Family Member HIV+
Treatment Supporter
Clinic Recommendation
Current Regimen
Fluconazole Use
Depression
Unsafe sex practices
Clinic Experience
Fatigue
Diarrhea
Lipodystrophy
Current CD4 count
ARV Reminders
Depression
Unsafe sex practices
Clinic Experience
Fatigue
Rash
Current CD4 count
ARV Reminders
Adherence
*These factors do not include those that were identified as baseline risk factors.
Marconi AIDS Pt Care STDs 2014
Proposed Individual-Level EWI
3
AUC = 0.8881
1
AUC = 0.7824
2
AUC = 0.8867
Next Steps
Validate EWI in Rural and Peri-Urban Settings
Test EWI prospectively to risk stratify patients
Implement EWI response to reduce VF
Goal: Increase Virological Suppression
Describe prevalence of
VF and HIVDR
Identify risk factors for VF
Design strategies to mitigate VF
Patient
Systems
PeopleDiagnostics
Question 4: If we could improve one thing about out clinics to improve retention and ART adherence what would it be?
Please make your selection...A. Shorter queues
B. Better diagnostics
C. More convenient clinics
D. Better facilities
E. Less expensive
F. Better relationship between Staff/Providers and patients
G. Other
Adult with Viral load suppressed rate at
6 months
DistrictTarget
FY 2014/15FY 2011/12 FY 2012/13 FY 2013/14 Progress Q3
VLS at 6m
FY 2013/14
Amajuba District Municipality 96.5 92.5 94.5 94.1 1,108
eThekwini Metropolitan Municipality 96.5 90.2 92.9 92.8 4,535
Harry Gwala District Municipality 96.5 74.4 78.9 83.5 1,577
iLembe District Municipality 96.5 90.3 91.7 0.0 0
Ugu District Municipality 96.5 92.1 93.2 91.3 3,941
uMgungundlovu District Municipality 96.5 80.2 80.9 84.5 915
Umkhanyakude District Municipality 96.5 92.5 90.5 91.3 1,884
Umzinyathi District Municipality 96.5 82.7 94.5 92.9 369
Uthukela District Municipality 96.5 87.6 89.7 93.1 1,676
Uthungulu District Municipality 96.5 67.5 78.2 83.9 4,250
Zululand District Municipality 96.5 83.3 87.1 92.6 718
KwaZulu-Natal 96.5 84.9 87.7 89.4 20,973
Adult percentage lost to follow up after
6 months ART
DistrictTarget
FY 2014/15FY 2011/12 FY 2012/13 FY 2013/14 Progress Q3
LTF at 6m
Q3 FY2013/14
Amajuba District Municipality 10.7 13.6 12.7 18.1 942
eThekwini Metropolitan Municipality 10.7 12.4 14.3 23.2 5,412
Harry Gwala District Municipality 10.7 8.6 10.9 20.4 1,515
iLembe District Municipality 10.7 6.5 11.6 1.9 7
Ugu District Municipality 10.7 8.7 9.7 19.7 2,224
uMgungundlovu District Municipality 10.7 11.4 17.2 18.8 1,068
Umkhanyakude District Municipality 10.7 6.1 8.5 24.0 2,256
Umzinyathi District Municipality 10.7 4.8 8.4 18.4 514
Uthukela District Municipality 10.7 6.9 10.5 15.0 1,482
Uthungulu District Municipality 10.7 9.6 10.8 17.6 2,038
Zululand District Municipality 10.7 8.8 10.9 17.3 665
KwaZulu-Natal 10.7 9.6 11.9 20.0 18,123
Adult with Viral load completion rate at
6 months
DistrictNDoH Target
FY 2014/15FY 2011/12 FY 2012/13 FY 2013/14 Progress Q3
VLD at 6m
FY 2013/14
Amajuba District Municipality 80 54.0 47.9 48.4 11,678
eThekwini Metropolitan Municipality 80 64.6 64.4 67.4 4,872
Harry Gwala District Municipality 80 65.1 55.3 44.1 1,148
iLembe District Municipality 80 50.2 44.0 42.6 23,041
Ugu District Municipality 80 38.6 36.2 32.4 1,178
uMgungundlovu District Municipality 80 26.5 30.6 29.6 4,888
Umkhanyakude District Municipality 80 41.4 39.4 35.4 1,888
Umzinyathi District Municipality 80 33.0 43.8 0.0 0
Uthukela District Municipality 80 37.7 42.9 53.4 4,318
Uthungulu District Municipality 80 38.6 35.2 28.4 1,083
Zululand District Municipality 80 43.4 37.6 32.0 2,064
KwaZulu-Natal 80 17.4 15.4 19.3 397
Henry Sunpath, MD, MPH
Developed out of RFVF and DReSSEndorsed by DOHSupported by REVAMP, CAPRISA, Adrenergy and MatCHeThekwini and uMkhanyakude District Process Improvement Project
VL Champion/Team, Data SynergyMetric evaluation, VL RegistersEnhanced Adherence CounselingEngaging Community Care Givers, Ward Based Outreach Teams and Primary Health Clinics
Sustained via HAST Quality Management ProgramAdopted by National Ministry
Jaysingh Brijkumar, MDSunpath Public Health Action 2018
Viral Load Monitoring Quality Improvement Program
Systems
Virologic Suppression
Virologic Completion
44
92-93%/83-86%
75-95%
Mark Siedner, MD
R01 AI124718Siedner HIV Clin Trials 2017
Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa (REVAMP)Diagnostics
• Genotype RT• Urine drug levels
Krista Dong, MD
Staff/Provider relationship critical
Traditional Healers committed to support culturally-sensitive HIV & TB care (300)
Link and retain patients enhanced by EWIDiana Jeang
The Integration of TB in Education and Care for HIV/AIDS (iTEACH)People
Dong JID 2007
VF and HIVDR are growing global concerns
Can we predict patients at risk?
Individual-level EWI at initiation and follow-up assists patient risk stratification as well as enable targeted and tailored interventions to be employed
Consider all aspects of the treatment paradigm with a key focus on those impacting adherence
Pharmacy refills and pill counts are insufficient to predict VF
Important to focus on both structural (institutional and economic) as well as psychosocial factors when designing interventions for patients
Need to externally validate model in other settings (rural and peri-urban) and include pharmacokinetics + minority variants
Can we prevent virologic failure?
Quality Improvement Programs (Systems)
Genotype Resistance Testing (Diagnostics)
Traditional Healers (People)
VF IS AN
EMERGENCY W/ OR W/O
RESISTANCE
Summary
McCord Hospital• Sabelo Dladla• Jane Hampton• Helga Holst• Sally John• Roma Maharaj• Phacia Ngubane• Claudia Ordonez• Melisha Pertab• Sifiso Shange
UKZN/DDMRI/RKK/Bethesda• Jaysingh Brijkumar• Kelly Gate• Michelle Gordon• Yunus Moosa• Jacinth Mudali• Sajiv Pertab• Selvan Pillay• Ansuri Singh• Henry Sunpath
Emory University• Hannah Appelbaum• Maneesha Chitanvis• Daniella Coker• Jonathan Colasanti• Carlos del Rio• Alex Edwards• Anna Hare• Monique Hennink• Diana Jeang• Brent Johnson• Rachel Kearns• Igho Ofotokun• Dina Pimenova• Nisa Pathan• Baohua Wu• Peng Wu
Harvard University• Kevin Ard• Krista Dong• Raj Gandhi• Daniel Kuritzkes• Jonathan Li• Richard Murphy• Mark Siedner
Support
NIH/NIAID R01 AI098558
NIH/NIAID R01 AI124718
Emory University CFAR
Harvard University CFAR
Adrenergy
Bayer Diagnostics
Gilead Pharmaceuticals
Acknowledgments
Special Thanks to the staff and patients of Sinikithemba, iThemba, RK Khan, Bethesda, Mkuze, Jozini, Clarewood, Wentworth, King
Dinizulu, Addington and Edendale Clinics…
…and my family for forbearance.